The risk for hepatocellular carcinoma (HCC) persists after hepatitis C virus (HCV) cure with direct-acting antivirals (DAAs) in individuals with HIV, though the likelihood of developing HCC decreases each year following treatment, according to study findings published in Clinical Infectious Diseases.
The investigators evaluated the 6-year probability of HCC assuming all eligible individuals initiated DAA therapy at baseline, using monthly data from the multinational HepCAUSAL collaboration, which includes cohorts from North America and Europe.
The findings suggest that HCC surveillance appears to be most crucial during the initial years post-DAA in people with HIV.
Read the full news story here.
/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
Source : Infectious Disease Advisor
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.